Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Executive Vice President | February 26, 2010 | March 02, 2010 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date February 26, 2010 · Filed March 02, 2010
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 110,509 |
Ending reported balance
After 2010-02-26 transaction · row 13
13 source rows · reconciled sequenceRow 1 · 2010-02-26 · Grant · Acquired 26,667 · Balance 123,843 F1: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Row 2 · 2010-02-26 · Sale · Disposed 3,634 · Balance 120,209 Row 3 · 2010-02-26 · Sale · Disposed 100 · Balance 120,109 Row 4 · 2010-02-26 · Sale · Disposed 400 · Balance 119,709 Row 5 · 2010-02-26 · Sale · Disposed 1,200 · Balance 118,509 Row 6 · 2010-02-26 · Sale · Disposed 3,500 · Balance 115,009 Row 7 · 2010-02-26 · Sale · Disposed 300 · Balance 114,709 Row 8 · 2010-02-26 · Sale · Disposed 100 · Balance 114,609 Row 9 · 2010-02-26 · Sale · Disposed 1,100 · Balance 113,509 Row 10 · 2010-02-26 · Sale · Disposed 100 · Balance 113,409 Row 11 · 2010-02-26 · Sale · Disposed 100 · Balance 113,309 Row 12 · 2010-02-26 · Sale · Disposed 2,600 · Balance 110,709 Row 13 · 2010-02-26 · Sale · Disposed 200 · Balance 110,509 |
Filing footnotes · ownership attribution and instrument terms
F1: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2008 Filed Feb 20, 2008 23:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 97,700 | $0.00 Strike: $55.56 | $0.00 |
DisclosureSEC source: 0001104659-08-011835 · a4.xml · derivative · entry 2 Bohuon Olivier · CIK 0001360215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,700 Underlying: common shares · 97,700 shares Expires 2018-02-14 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. The option becomes exercisable in annual increments of 32,567 on 2/15/2009, 32,567 on 2/15/10, and 32,566 on 2/15/11. Read SEC document |
| August 07, 2007 Filed Aug 9, 2007 21:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 7,179 | $0.00 Strike: $41.78 | $0.00 |
DisclosureSEC source: 0001104659-07-061065 · a4.xml · derivative · entry 7 Bohuon Olivier · CIK 0001360215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 7,179 shares Expires 2013-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option, including replacement option feature granted pursuant to Abbott Laboratories Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| August 07, 2007 Filed Aug 9, 2007 21:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 31,920 | $0.00 Strike: $41.03 | $0.00 |
DisclosureSEC source: 0001104659-07-061065 · a4.xml · derivative · entry 6 Bohuon Olivier · CIK 0001360215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 31,920 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option, including replacement option feature granted pursuant to Abbott Laboratories Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| August 07, 2007 Filed Aug 9, 2007 21:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 12,000 | $0.00 Strike: $41.78 | $0.00 |
DisclosureSEC source: 0001104659-07-061065 · a4.xml · derivative · entry 5 Bohuon Olivier · CIK 0001360215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,023 Underlying: Common shares · 12,000 shares Expires 2013-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option, including replacement option feature granted pursuant to Abbott Laboratories Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| August 07, 2007 Filed Aug 9, 2007 21:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 51,099 | $55.00 | $2,810,445.00 |
DisclosureSEC source: 0001104659-07-061065 · a4.xml · nonDerivative · entry 4 Bohuon Olivier · CIK 0001360215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,664 Read SEC document |
| August 07, 2007 Filed Aug 9, 2007 21:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 31,920 | $41.03 | $1,309,731.86 |
DisclosureSEC source: 0001104659-07-061065 · a4.xml · nonDerivative · entry 3 Bohuon Olivier · CIK 0001360215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,763 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2007 Filed Aug 9, 2007 21:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 19,179 | $41.78 | $801,367.66 |
DisclosureSEC source: 0001104659-07-061065 · a4.xml · nonDerivative · entry 2 Bohuon Olivier · CIK 0001360215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,843 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 24, 2007 Filed Aug 9, 2007 21:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 4,667 | $57.21 | $266,999.07 |
DisclosureSEC source: 0001104659-07-061065 · a4.xml · nonDerivative · entry 1 Bohuon Olivier · CIK 0001360215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,664 F1 · kind: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 17, 2007 Filed Feb 21, 2007 23:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 4,167 | $52.49 | $218,725.83 |
DisclosureSEC source: 0001104659-07-012793 · a4.xml · nonDerivative · entry 1 Bohuon Olivier · CIK 0001360215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,997 F1 · kind: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 16, 2007 Filed Feb 21, 2007 23:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantRestricted Stock Unit · Derivative | 17,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-07-012793 · a4.xml · derivative · entry 3 Bohuon Olivier · CIK 0001360215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: common shares · 17,000 shares Expires not disclosed F3 · security: These are restricted stock units awarded under the Abbott Laboratories 1996 Incentive Stock Program. The units generally vest on the third anniversary of their grant date and include the right to have stock withheld for tax purposes. Each unit represents the contingent right to receive one Abbott common share. F3 · derivative.exercise_date: These are restricted stock units awarded under the Abbott Laboratories 1996 Incentive Stock Program. The units generally vest on the third anniversary of their grant date and include the right to have stock withheld for tax purposes. Each unit represents the contingent right to receive one Abbott common share. F3 · derivative.expiration_date: These are restricted stock units awarded under the Abbott Laboratories 1996 Incentive Stock Program. The units generally vest on the third anniversary of their grant date and include the right to have stock withheld for tax purposes. Each unit represents the contingent right to receive one Abbott common share. Read SEC document |
| February 16, 2007 Filed Feb 21, 2007 23:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 83,000 | $0.00 Strike: $52.54 | $0.00 |
DisclosureSEC source: 0001104659-07-012793 · a4.xml · derivative · entry 2 Bohuon Olivier · CIK 0001360215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,000 Underlying: common shares · 83,000 shares Expires 2017-02-15 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. The option becomes exercisable in annual increments of 27,667 on 2/16/2008, 27,667 on 2/16/09, and 27,666 on 2/16/10. Read SEC document |
| April 24, 2006 Filed Apr 26, 2006 21:33 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 47,000 | $0.00 Strike: $41.48 | $0.00 |
DisclosureSEC source: 0001104659-06-027989 · a4.xml · derivative · entry 1 Bohuon Olivier · CIK 0001360215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,000 Underlying: common shares · 47,000 shares Expires 2016-04-23 F1 · security: Employee stock options granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) Rule 16b-3. The option becomes exercisable in annual increments of 15,667 on 4/24/2007, 15,667 on 4/24/2008 and 15,666 on 4/24/2009. Read SEC document |
| April 24, 2006 Filed May 1, 2006 22:03 UTC Amendment | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 47,000 | $0.00 Strike: $41.48 | $0.00 |
DisclosureSEC source: 0001104659-06-029869 · a4a.xml · derivative · entry 1 Bohuon Olivier · CIK 0001360215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,000 Underlying: common shares · 47,000 shares Expires 2016-04-23 F1 · security: Employee stock options granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. The option becomes exercisable in annual increments of 15,667 on 4/24/2007, 15,667 on 4/24/2008 and 15,666 on 4/24/2009. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.